Page 2 of GlobalData

According to GlobalData, while the majority of the 22 vaccine candidates currently in development rely on traditional approaches, mRNA vaccines…

Many countries, particularly in Europe, have stricter reimbursement rules than the guidelines recommend, meaning that access will be an ongoing…

To address this situation, it is essential to foster open communication and collaboration between physicians and patients, GlobalData stated.

The VERVE-101 clinical trial shows that this therapeutic approach can also be used to target genes associated with cardiovascular disease…

The US is one of the most important markets for Tasigna, as it contributed 39% of the drug’s total historical…

These results of AnaptysBio’s imsidolimab gives potential to the company to establish itself as a future player in the GPP…